醒脑静注射液联合阿替普酶静脉溶栓治疗急性缺血性脑卒中的临床价值研究

Research on Clinical Value of Xingnaojing Injection Combined with Intravenous Thrombolysis with Opioppenzyme in Treatment of Acute Cerebral Infarction

目的观察对急性缺血性脑卒中应用阿替普酶静脉溶酸+醒脑静注射液的疗效分析。方法选取该院2016年5月—2017年6月收治的急性缺血性脑卒中49例,根据随机数字法将研究对象分为两组,分别为对照组24例,观察组25例;采用阿替普酶静脉溶栓给予对照组治疗,在此基础上观察组联合使用醒脑静注射治疗,持续治疗14 d后,综合评估两组疗效。结果对照组24例CIS患者总有效率79.17%低于观察组94.00%,差异有统计学意义(P<0.05);观察组25例CIS患者GCS评分(14.9±2.2)分高于对照组(12.3±1.4)分,观察组NIHSS评分(3.5±0.8)分低于对照组(4.7±1.6)分,差异有统计学意义(P<0.05)。结论对治疗CIS采用阿替普酶静脉溶栓+中药制剂醒脑静注射液,药物不良反应低、安全性高,且具有良好疗效,值得临床推广。

Objective To observe the clinical value of xingnaojing injection combined with intravenous thrombolysis with opioppenzyme in treatment of acute cerebral infarction. Methods 49 cases of patients with acute cerebral infarction admitted and treated in our hospital from May 2016 to June 2017 were selected and randomly divided into two groups, the control group with 24 cases were treated with intravenous thrombolysis with opioppenzyme, while the observation group with 25 cases were treated with xingnaojing injection combined with intravenous thrombolysis with opioppenzyme, and the curative effect was evaluated comprehensively after 14 d treatment. Results The total treatment effective rate in the control group was lower than that in the observation group（79.17% vs 94.00%）, and the difference was statistically significant（P〈0.05）, and the GCS score of CIS patients in the observation group was higher than that in the control group[（14.9±2.2） points vs（12.3±1.4）points], and the NIHSS score in the observation group was lower than that in the control group[（3.5±0.8）points vs（4.7±1.6）points], and the difference was statistically significant（P〈0.05）. Conclusion The drug adverse reactions of xingnaojing injection combined with intravenous thrombolysis with opioppenzyme in treatment of acute cerebral infarction is low with high safety and good curative effect, and it is worth clinical promotion.